Busuttil W J, Fabri B M
Cardiothoracic Centre, Liverpool, UK.
Postgrad Med J. 1995 Jul;71(837):390-2. doi: 10.1136/pgmj.71.837.390.
Prosthetic valve thrombogenicity and bleeding complications associated with life-long anticoagulation are constant potential causes of morbidity and mortality following prosthetic valve implantation. The conflict between over- and under-anticoagulation is even more of a problem when other surgical interventions are required. Very few clinical trials have addressed this issue. We propose some guidelines based on the concept of risk-adjusted intensity of anticoagulation but stress the need for caution with interpretation of these recommendations.
人工瓣膜的血栓形成倾向以及与终身抗凝相关的出血并发症,一直都是人工瓣膜植入术后发病和死亡的潜在原因。当需要进行其他外科手术干预时,抗凝过度与不足之间的矛盾就更是一个问题。很少有临床试验涉及这一问题。我们基于风险调整抗凝强度的概念提出了一些指导原则,但强调在解读这些建议时需谨慎。